Hims & Hers Health (NYSE:HIMS) Stock Crosses Above 50-Day Moving Average - Here's Why

Key Points

• HIMS shares rose 5.2% and crossed above their 50-day moving average of $29.15, trading as high as $29.81 amid heavy volume.
• Reported HHS “enforcement discretion” allowing temporary compounding of six peptides could expand Hims & Hers’ treatment offerings and ease near-term regulatory pressure, though the policy’s long-term impact remains uncertain.
• Legal and financial risks persist, including FTC and state privacy litigation, a securities class action, and a recent quarterly EPS miss. Analysts maintain an overall “Hold” rating with an average price target of $32.43.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s share price crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $29.15 and traded as high as $29.81. Hims & Hers Health shares last traded at $29.3610, with a volume of 12,251,814 shares traded.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: The Department of Health and Human Services reportedly said it would temporarily use “enforcement discretion” to allow compounding of six peptides. The decision could expand Hims & Hers’ treatment offerings and reduce near-term regulatory pressure on its compounded-medication business, supporting the stock’s move higher. HIMS stock jumps after HHS temporarily clears compounding of six peptides
• Positive Sentiment: The HHS action is being viewed as a potential relief for telehealth providers that rely on compounded therapies. However, the policy is temporary, so the longer-term commercial benefit remains dependent on future regulatory decisions. Hims & Hers jumped as HHS uses enforcement discretion to open peptide compounding
• Neutral Sentiment: Hims & Hers is seeking dismissal of a Federal Trade Commission and states’ data-privacy case. A successful dismissal could remove a legal risk, but the outcome is unresolved. Hims & Hers seeks dismissal of FTC and states’ data privacy case
• Negative Sentiment: Multiple law firms reiterated that investors have until November 2, 2026, to seek lead-plaintiff status in a securities class action covering purchases from August 4, 2025, through July 29, 2026. The case stems from allegations tied to the FTC’s complaint, including alleged business misconduct, privacy, and billing practices. These are allegations, not established findings, but the litigation creates reputational, financial, and management risks. HIMS class-action deadline alert
• Negative Sentiment: Investor commentary also highlights the possibility of a substantial further decline, underscoring continued volatility and uncertainty around HIMS’s legal exposure, regulatory outlook, and profitability. Can Hims & Hers stock fall 30%?

Analysts Set New Price Targets

Several research firms have weighed in on HIMS. Citigroup decreased their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set a "neutral" rating on the stock in a report on Tuesday, August 11th. TD Cowen raised their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a "hold" rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a "hold" rating in a research report on Tuesday, August 11th. Truist Financial lifted their price target on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a "hold" rating in a research report on Monday, August 24th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Hims & Hers Health in a report on Friday, August 7th. Three research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $32.43.

Hims & Hers Health Trading Up 5.2%

The stock has a market capitalization of $6.85 billion, a PE ratio of -46.60 and a beta of 2.44. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The business's 50-day moving average is $29.15 and its two-hundred day moving average is $27.11.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The company had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business's revenue was up 38.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.17 EPS. On average, analysts anticipate that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Oluyemi Okupe sold 2,000 shares of the firm's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $29.70, for a total transaction of $59,400.00. Following the transaction, the chief financial officer owned 234,527 shares in the company, valued at $6,965,451.90. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 3,461 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $29.06, for a total value of $100,576.66. Following the transaction, the insider directly owned 297,348 shares in the company, valued at approximately $8,640,932.88. This trade represents a 1.15% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 130,443 shares of company stock valued at $3,731,426. Insiders own 11.76% of the company's stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Bank of America Corp DE boosted its stake in shares of Hims & Hers Health by 194.4% during the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock worth $90,465,000 after acquiring an additional 2,877,550 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Hims & Hers Health in the 2nd quarter valued at approximately $46,220,000. Bienville Capital Management LLC purchased a new position in Hims & Hers Health in the 2nd quarter valued at approximately $27,242,000. Principal Financial Group Inc. raised its holdings in Hims & Hers Health by 97.3% during the first quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company's stock worth $26,620,000 after purchasing an additional 632,282 shares during the last quarter. Finally, Southpoint Capital Advisors LP acquired a new position in Hims & Hers Health during the first quarter worth $10,380,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.